Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 10

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 16
Chunk 10
---
 Jeremy Bender, Ph.D., M.B.A.

    /s/ Charles N. York II, M.B.A.
     
    Chief Operating Officer and Chief Financial Officer(Principal Financial and Accounting Officer)
     
    February 25, 2025

    Charles N. York II, M.B.A.

    /s/ Garry Nicholson, M.B.A.
     
    Chair and Director
     
    February 25, 2025

    Garry Nicholson

    /s/ Habib Dable
     
    Director
     
    February 25, 2025

    Habib Dable

    /s/ Scott Garland
     
    Director
     
    February 25, 2025

    Scott Garland

    /s/ Michael Gladstone
     
    Director
     
    February 25, 2025

    Michael Gladstone

    /s/ William Grossman, M.D., Ph.D.
     
    Director
     
    February 25, 2025

    William Grossman, M.D., Ph.D.

    /s/ Natalie Holles
     
    Director
     
    February 25, 2025

    Natalie Holles

    /s/ John A. Josey, Ph.D., M.B.A.
     
    Director
     
    February 25, 2025

    John A. Josey, Ph.D., M.B.A.

    /s/ Saira Ramasastry, M.S., M.Phil.
     
    Director
     
    February 25, 2025

    Saira Ramasastry, M.S., M.Phil.

133

INDEX TO FINANCIAL STATEMENTS

    Report of Independent Registered Public Accounting Firm (PCAOB ID: 238)
    F-2

    Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)
    F-5

    Balance Sheets
    F-6

    Statements of Operations
    F-7

    Statements of Comprehensive Loss
    F-8

    Statements of Stockholders’ Equity
    F-9

    Statements of Cash Flows
    F-10

    Notes to Financial Statements
    F-11

F-1

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of Day One Biopharmaceuticals, Inc.

Opinions on the Financial Statements and Internal Control over Financial ReportingWe have audited the accompanying balance sheets of Day One